entertainment -WSS

entertainment

author：knowledge 2025-10-02 02:16:23 - browse：935

Lung cancer under microscope — coverage from STAT — Lung cancer Adobe

CHICAGO — Delfi Diagnostics, a company seeking to develop liquid biopsy tests to help screen for lung cancer, published a scientific paper on Monday describing key aspects of the test and unveiled the design of a key clinical trial.

Delfi also announced that the Merck Global Health Innovation Fund, the VC arm of the drug giant, has made an investment of an undisclosed amount in the company.

Unlike Grail, a unit of Illumina, or Exact Sciences, which seeks to develop a blood test that can be used to screen for multiple types of cancer, Delfi is focusing on a single disease — lung cancer — in which the utility of screening with existing technology is not in dispute. Using low-dose CT scans to detect lung cancer is considered an established technology for people at higher risk of lung cancer. However, far too few people get screened.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Change Healthcare outage fallout shows need for new oversight

leisure time

WSS

Large hospital system sues Multiplan for low

Change Healthcare outage fallout shows need for new oversight

Covid's long

First U.S. drug developed to treat liver disease MASH is approved

After John Oliver segment, STAT readers share their opioid

TB outbreak tied to bone grafts underscores testing shortcomings

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

DIEP, the 'gold standard' of breast reconstruction, is under threat

Covid's long

ChatGPT in medicine: STAT answers readers' burning questions

Pharma budget tightening trickles down to Doximity

BioMarin wins approval for gene therapy to treat hemophilia A

HHS secretary Becerra pressed on Change HealthCare cyberattack

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: Bristol, Sangamo, Gilead, and more

knowledge

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Medicare coverage of Wegovy, once blocked, now looks possible

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

WuXi out of biotech trade group, U.S. and China relations to blame

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

hotspot

leisure time

hotspot

Wikipedia